サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1067089

細胞株開発の世界市場：～2027年

Cell Line Development Market Research Report Forecast till 2027
出版日: | 発行: Market Research Future | ページ情報: 英文 144 Pages | 納期: 即納可能 即納可能とは

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=155.76円
細胞株開発の世界市場：～2027年
出版日: 2022年03月22日
発行: Market Research Future
ページ情報: 英文 144 Pages
納期: 即納可能 即納可能とは
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界の細胞株開発の市場規模は、予測期間中11.3%のCAGRで推移し、2027年末には108億2,990万米ドルの規模に成長すると予測されています。

モノクローナル抗体への需要の拡大、バイオテクノロジー産業の成長、世界中で増加するワクチン生産などの要因が同市場の成長を推進しています。一方で、安定した細胞株開発の複雑さ、スキルを有する人材の必要性、高い維持費などの課題が市場成長を抑制する見通しです。

当レポートでは、世界の細胞株開発の市場を調査し、市場概要、市場成長への各種影響因子の分析、主要動向、市場規模の推移・予測、各種区分・地域別の詳細分析、競合環境、主要企業のプロファイルなどをまとめています。

目次

第1章 エグゼクティブサマリー

第2章 イントロダクション

第3章 調査手法

第4章 市場力学

  • 概要
  • 促進要因
  • 抑制要因
  • 市場機会

第5章 市場要因分析

  • サプライチェーン分析
  • ポーターのファイブフォース分析
  • COVID-19：世界の細胞株開発市場に与える影響

第6章 世界の細胞株開発市場：製品別

  • 装置
  • 試薬・培地

第7章 世界の細胞株開発市場：原料別

  • 哺乳類
  • 非哺乳類
    • 両生類
    • 昆虫

第8章 世界の細胞株開発市場：タイプ別

  • 組換え細胞株
  • ハイブリドーマ
  • 連続細胞株
  • 初代細胞株

第9章 世界の細胞株開発市場：用途別

  • バイオプロダクション
    • 市場動向・比較成長率：二重特異性/多重特異性抗体および細胞株開発市場
    • 抗体製造
    • 酵素製造
    • ホルモン製造
    • その他
  • 創薬
  • 組織工学
  • その他

第10章 世界の細胞株開発市場：地域別

  • 北米
  • 欧州
  • アジア太平洋
  • その他の地域

第11章 競合情勢

  • 概要
  • 世界の細胞株開発市場：企業シェア分析
  • 競合ベンチマーキング
  • 主要成長戦略
  • 開発数の点で主要企業
  • 主な開発分析
  • 主な展開・成長戦略
  • 財務マトリックス

第12章 企業プロファイル

  • LONZA GROUP
  • SELEXIS SA
  • BOEHRINGER INGELHEIM INTERNATIONAL GMBH
  • THERMO FISHER SCIENTIFIC INC.
  • WUXI BIOLOGICS
  • RENTSCHLER BIOPHARMA SE
  • HORIZON DISCOVERY LTD
  • SARTORIUS AG
  • MERCK KGAA
  • FUJIFILM DIOSYNTH BIOTECHNOLOGIES INC.

第13章 付録

図表

LIST OF TABLES

  • TABLE 1 LIST OF ASSUMPTIONS & LIMITATIONS
  • TABLE 2 GLOBAL: CELL LINE DEVELOPMENT MARKET, BY PRODUCT, 2018-2027 (USD MILLION)
  • TABLE 3 COMMON CELL LINE DEVELOPMENT EQUIPMENT AND THEIR FUNCTION
  • TABLE 4 GLOBAL: CELL LINE DEVELOPMENT MARKET, FOR EQUIPMENT, BY REGION, 2018-2027 (USD MILLION)
  • TABLE 5 GLOBAL: CELL LINE DEVELOPMENT MARKET, FOR REAGENTS & MEDIA, BY REGION, 2018-2027 (USD MILLION)
  • TABLE 6 GLOBAL: CELL LINE DEVELOPMENT MARKET, BY SOURCE, 2018-2027 (USD MILLION)
  • TABLE 7 GLOBAL: CELL LINE DEVELOPMENT MARKET, BY NON-MAMMALIAN TYPE, 2018-2027 (USD MILLION)
  • TABLE 8 GLOBAL: CELL LINE DEVELOPMENT MARKET, FOR MAMMALIAN, BY REGION, 2018-2027 (USD MILLION)
  • TABLE 9 GLOBAL: CELL LINE DEVELOPMENT MARKET, FOR NON-MAMMALIAN, BY REGION, 2018-2027 (USD MILLION)
  • TABLE 10 GLOBAL: CELL LINE DEVELOPMENT MARKET, FOR AMPHIBIANS, BY REGION, 2018-2027 (USD MILLION)
  • TABLE 11 GLOBAL: CELL LINE DEVELOPMENT MARKET, FOR INSECTS, BY REGION, 2018-2027 (USD MILLION)
  • TABLE 12 GLOBAL: CELL LINE DEVELOPMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
  • TABLE 13 GLOBAL: CELL LINE DEVELOPMENT MARKET, FOR RECOMBINANT CELL LINES, BY REGION, 2018-2027 (USD MILLION)
  • TABLE 14 GLOBAL: CELL LINE DEVELOPMENT MARKET, FOR ANTIBODY SCREENING, BY REGION, 2018-2027 (USD MILLION)
  • TABLE 15 GLOBAL: CELL LINE DEVELOPMENT MARKET, FOR CONTINUOUS CELL LINES, BY REGION, 2018-2027 (USD MILLION)
  • TABLE 16 GLOBAL: CELL LINE DEVELOPMENT MARKET, FOR PRIMARY CELL LINES, BY REGION, 2018-2027 (USD MILLION)
  • TABLE 17 GLOBAL: CELL LINE DEVELOPMENT MARKET, BY APPLICATION, 2018-2027 (USD MILLION)
  • TABLE 18 GLOBAL: CELL LINE DEVELOPMENT MARKET, BY BIOPRODUCTION TYPE, 2018-2027 (USD MILLION)
  • TABLE 19 GLOBAL: CELL LINE DEVELOPMENT MARKET, BY ANTIBODY PRODUCTION TYPE, 2018-2027 (USD MILLION)
  • TABLE 20 RECENT MARKET TRENDS INVOLVING BISPECIFIC ANTIBODIES
  • TABLE 21 PRODUCT PIPELINE
  • TABLE 22 GLOBAL: CELL LINE DEVELOPMENT MARKET, FOR BIOPRODUCTION, BY REGION, 2018-2027 (USD MILLION)
  • TABLE 23 GLOBAL: CELL LINE DEVELOPMENT MARKET, FOR ANTIBODY PRODUCTION, BY REGION, 2018-2027 (USD MILLION)
  • TABLE 24 GLOBAL: CELL LINE DEVELOPMENT MARKET, FOR MONO, BY REGION, 2018-2027 (USD MILLION)
  • TABLE 25 GLOBAL: CELL LINE DEVELOPMENT MARKET, FOR BI/MULTI, BY REGION, 2018-2027 (USD MILLION)
  • TABLE 26 GLOBAL: CELL LINE DEVELOPMENT MARKET, FOR ENZYME PRODUCTION, BY REGION, 2018-2027 (USD MILLION)
  • TABLE 27 GLOBAL: CELL LINE DEVELOPMENT MARKET, FOR HORMONE PRODUCTION, BY REGION, 2018-2027 (USD MILLION)
  • TABLE 28 GLOBAL: CELL LINE DEVELOPMENT MARKET, FOR OTHERS, BY REGION, 2018-2027 (USD MILLION)
  • TABLE 29 GLOBAL: CELL LINE DEVELOPMENT MARKET, FOR DRUG DISCOVERY, BY REGION, 2018-2027 (USD MILLION)
  • TABLE 30 GLOBAL: CELL LINE DEVELOPMENT MARKET, FOR TISSUE ENGINEERING, BY REGION, 2018-2027 (USD MILLION)
  • TABLE 31 GLOBAL: CELL LINE DEVELOPMENT MARKET, FOR OTHERS, BY REGION, 2018-2027 (USD MILLION)
  • TABLE 32 GLOBAL: CELL LINE DEVELOPMENT MARKET, BY REGION, 2018-2027 (USD MILLION)
  • TABLE 33 NORTH AMERICA: CELL LINE DEVELOPMENT MARKET, BY COUNTRY, 2018-2027 (USD MILLION)
  • TABLE 34 NORTH AMERICA: CELL LINE DEVELOPMENT MARKET, BY PRODUCT, 2018-2027 (USD MILLION)
  • TABLE 35 NORTH AMERICA: CELL LINE DEVELOPMENT MARKET, BY SOURCE, 2018-2027, (USD MILLION)
  • TABLE 36 NORTH AMERICA: CELL LINE DEVELOPMENT MARKET, FOR NON-MAMMALIAN, BY TYPE, 2018-2027, (USD MILLION)
  • TABLE 37 NORTH AMERICA: CELL LINE DEVELOPMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
  • TABLE 38 NORTH AMERICA: CELL LINE DEVELOPMENT MARKET, BY APPLICATION, 2018-2027 (USD MILLION)
  • TABLE 39 NORTH AMERICA: CELL LINE DEVELOPMENT MARKET, FOR BIOPRODUCTION, BY TYPE, 2018-2027 (USD MILLION)
  • TABLE 40 NORTH AMERICA: CELL LINE DEVELOPMENT MARKET, FOR ANTIBODY PRODUCTION, BY TYPE, 2018-2027 (USD MILLION)
  • TABLE 41 US: CELL LINE DEVELOPMENT MARKET, BY PRODUCT, 2018-2027 (USD MILLION)
  • TABLE 42 US: CELL LINE DEVELOPMENT MARKET, BY SOURCE, 2018-2027, (USD MILLION)
  • TABLE 43 US: CELL LINE DEVELOPMENT MARKET, FOR NON-MAMMALIAN, BY TYPE, 2018-2027, (USD MILLION)
  • TABLE 44 US: CELL LINE DEVELOPMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
  • TABLE 45 US: CELL LINE DEVELOPMENT MARKET, BY APPLICATION, 2018-2027 (USD MILLION)
  • TABLE 46 US: CELL LINE DEVELOPMENT MARKET, FOR BIOPRODUCTION, BY TYPE, 2018-2027 (USD MILLION)
  • TABLE 47 US: CELL LINE DEVELOPMENT MARKET, FOR ANTIBODY PRODUCTION, BY TYPE, 2018-2027 (USD MILLION)
  • TABLE 48 CANADA: CELL LINE DEVELOPMENT MARKET, BY PRODUCT, 2018-2027 (USD MILLION)
  • TABLE 49 CANADA: CELL LINE DEVELOPMENT MARKET, BY SOURCE, 2018-2027, (USD MILLION)
  • TABLE 50 CANADA: CELL LINE DEVELOPMENT MARKET, FOR NON-MAMMALIAN, BY TYPE, 2018-2027, (USD MILLION)
  • TABLE 51 CANADA: CELL LINE DEVELOPMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
  • TABLE 52 CANADA: CELL LINE DEVELOPMENT MARKET, BY APPLICATION, 2018-2027 (USD MILLION)
  • TABLE 53 CANADA: CELL LINE DEVELOPMENT MARKET, FOR BIOPRODUCTION, BY TYPE, 2018-2027 (USD MILLION)
  • TABLE 54 CANADA: CELL LINE DEVELOPMENT MARKET, FOR ANTIBODY PRODUCTION, BY TYPE, 2018-2027 (USD MILLION)
  • TABLE 55 EUROPE: CELL LINE DEVELOPMENT MARKET, BY COUNTRY, 2018-2027 (USD MILLION)
  • TABLE 56 EUROPE: CELL LINE DEVELOPMENT MARKET, BY PRODUCT, 2018-2027 (USD MILLION)
  • TABLE 57 EUROPE: CELL LINE DEVELOPMENT MARKET, BY SOURCE, 2018-2027, (USD MILLION)
  • TABLE 58 EUROPE: CELL LINE DEVELOPMENT MARKET, FOR NON-MAMMALIAN, BY TYPE, 2018-2027, (USD MILLION)
  • TABLE 59 EUROPE: CELL LINE DEVELOPMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
  • TABLE 60 EUROPE: CELL LINE DEVELOPMENT MARKET, BY APPLICATION, 2018-2027 (USD MILLION)
  • TABLE 61 EUROPE: CELL LINE DEVELOPMENT MARKET, FOR BIOPRODUCTION, BY TYPE, 2018-2027 (USD MILLION)
  • TABLE 62 EUROPE: CELL LINE DEVELOPMENT MARKET, FOR ANTIBODY PRODUCTION, BY TYPE, 2018-2027 (USD MILLION)
  • TABLE 63 GERMANY: CELL LINE DEVELOPMENT MARKET, BY PRODUCT, 2018-2027 (USD MILLION)
  • TABLE 64 GERMANY: CELL LINE DEVELOPMENT MARKET, BY SOURCE, 2018-2027, (USD MILLION)
  • TABLE 65 GERMANY: CELL LINE DEVELOPMENT MARKET, FOR NON-MAMMALIAN, BY TYPE, 2018-2027, (USD MILLION)
  • TABLE 66 GERMANY: CELL LINE DEVELOPMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
  • TABLE 67 GERMANY: CELL LINE DEVELOPMENT MARKET, BY APPLICATION, 2018-2027 (USD MILLION)
  • TABLE 68 GERMANY: CELL LINE DEVELOPMENT MARKET, FOR BIOPRODUCTION, BY TYPE, 2018-2027 (USD MILLION)
  • TABLE 69 GERMANY: CELL LINE DEVELOPMENT MARKET, FOR ANTIBODY PRODUCTION, BY TYPE, 2018-2027 (USD MILLION)
  • TABLE 70 UK: CELL LINE DEVELOPMENT MARKET, BY PRODUCT, 2018-2027 (USD MILLION)
  • TABLE 71 UK: CELL LINE DEVELOPMENT MARKET, BY SOURCE, 2018-2027, (USD MILLION)
  • TABLE 72 UK: CELL LINE DEVELOPMENT MARKET, FOR NON-MAMMALIAN, BY TYPE, 2018-2027, (USD MILLION)
  • TABLE 73 UK: CELL LINE DEVELOPMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
  • TABLE 74 UK: CELL LINE DEVELOPMENT MARKET, BY APPLICATION, 2018-2027 (USD MILLION)
  • TABLE 75 UK: CELL LINE DEVELOPMENT MARKET, FOR BIOPRODUCTION, BY TYPE, 2018-2027 (USD MILLION)
  • TABLE 76 UK: CELL LINE DEVELOPMENT MARKET, FOR ANTIBODY PRODUCTION, BY TYPE, 2018-2027 (USD MILLION)
  • TABLE 77 FRANCE: CELL LINE DEVELOPMENT MARKET, BY PRODUCT, 2018-2027 (USD MILLION)
  • TABLE 78 FRANCE: CELL LINE DEVELOPMENT MARKET, BY SOURCE, 2018-2027, (USD MILLION)
  • TABLE 79 FRANCE: CELL LINE DEVELOPMENT MARKET, FOR NON-MAMMALIAN, BY TYPE, 2018-2027, (USD MILLION)
  • TABLE 80 FRANCE: CELL LINE DEVELOPMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
  • TABLE 81 FRANCE: CELL LINE DEVELOPMENT MARKET, BY APPLICATION, 2018-2027 (USD MILLION)
  • TABLE 82 FRANCE: CELL LINE DEVELOPMENT MARKET, FOR BIOPRODUCTION, BY TYPE, 2018-2027 (USD MILLION)
  • TABLE 83 FRANCE: CELL LINE DEVELOPMENT MARKET, FOR ANTIBODY PRODUCTION, BY TYPE, 2018-2027 (USD MILLION)
  • TABLE 84 ITALY: CELL LINE DEVELOPMENT MARKET, BY PRODUCT, 2018-2027 (USD MILLION)
  • TABLE 85 ITALY: CELL LINE DEVELOPMENT MARKET, BY SOURCE, 2018-2027, (USD MILLION)
  • TABLE 86 ITALY: CELL LINE DEVELOPMENT MARKET, FOR NON-MAMMALIAN, BY TYPE, 2018-2027, (USD MILLION)
  • TABLE 87 ITALY: CELL LINE DEVELOPMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
  • TABLE 88 ITALY: CELL LINE DEVELOPMENT MARKET, BY APPLICATION, 2018-2027 (USD MILLION)
  • TABLE 89 ITALY: CELL LINE DEVELOPMENT MARKET, FOR BIOPRODUCTION, BY TYPE, 2018-2027 (USD MILLION)
  • TABLE 90 ITALY: CELL LINE DEVELOPMENT MARKET, FOR ANTIBODY PRODUCTION, BY TYPE, 2018-2027 (USD MILLION)
  • TABLE 91 SPAIN: CELL LINE DEVELOPMENT MARKET, BY PRODUCT, 2018-2027 (USD MILLION)
  • TABLE 92 SPAIN: CELL LINE DEVELOPMENT MARKET, BY SOURCE, 2018-2027, (USD MILLION)
  • TABLE 93 SPAIN: CELL LINE DEVELOPMENT MARKET, FOR NON-MAMMALIAN, BY TYPE, 2018-2027, (USD MILLION)
  • TABLE 94 SPAIN: CELL LINE DEVELOPMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
  • TABLE 95 SPAIN: CELL LINE DEVELOPMENT MARKET, BY APPLICATION, 2018-2027 (USD MILLION)
  • TABLE 96 SPAIN: CELL LINE DEVELOPMENT MARKET, FOR BIOPRODUCTION, BY TYPE, 2018-2027 (USD MILLION)
  • TABLE 97 SPAIN: CELL LINE DEVELOPMENT MARKET, FOR ANTIBODY PRODUCTION, BY TYPE, 2018-2027 (USD MILLION)
  • TABLE 98 SWITZERLAND: CELL LINE DEVELOPMENT MARKET, BY PRODUCT, 2018-2027 (USD MILLION)
  • TABLE 99 SWITZERLAND: CELL LINE DEVELOPMENT MARKET, BY SOURCE, 2018-2027, (USD MILLION)
  • TABLE 100 SWITZERLAND: CELL LINE DEVELOPMENT MARKET, FOR NON-MAMMALIAN, BY TYPE, 2018-2027, (USD MILLION)
  • TABLE 101 SWITZERLAND: CELL LINE DEVELOPMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
  • TABLE 102 SWITZERLAND: CELL LINE DEVELOPMENT MARKET, BY APPLICATION, 2018-2027 (USD MILLION)
  • TABLE 103 SWITZERLAND: CELL LINE DEVELOPMENT MARKET, FOR BIOPRODUCTION, BY TYPE, 2018-2027 (USD MILLION)
  • TABLE 104 SWITZERLAND: CELL LINE DEVELOPMENT MARKET, FOR ANTIBODY PRODUCTION, BY TYPE, 2018-2027 (USD MILLION)
  • TABLE 105 REST OF EUROPE: CELL LINE DEVELOPMENT MARKET, BY PRODUCT, 2018-2027 (USD MILLION)
  • TABLE 106 REST OF EUROPE: CELL LINE DEVELOPMENT MARKET, BY SOURCE, 2018-2027, (USD MILLION)
  • TABLE 107 REST OF EUROPE: CELL LINE DEVELOPMENT MARKET, FOR NON-MAMMALIAN, BY TYPE, 2018-2027, (USD MILLION)
  • TABLE 108 REST OF EUROPE: CELL LINE DEVELOPMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
  • TABLE 109 REST OF EUROPE: CELL LINE DEVELOPMENT MARKET, BY APPLICATION, 2018-2027 (USD MILLION)
  • TABLE 110 REST OF EUROPE: CELL LINE DEVELOPMENT MARKET, FOR BIOPRODUCTION, BY TYPE, 2018-2027 (USD MILLION)
  • TABLE 111 REST OF EUROPE: CELL LINE DEVELOPMENT MARKET, FOR ANTIBODY PRODUCTION, BY TYPE, 2018-2027 (USD MILLION)
  • TABLE 112 ASIA-PACIFIC: CELL LINE DEVELOPMENT MARKET, BY COUNTRY, 2018-2027 (USD MILLION)
  • TABLE 113 ASIA PACIFIC: CELL LINE DEVELOPMENT MARKET, BY PRODUCT, 2018-2027 (USD MILLION)
  • TABLE 114 ASIA-PACIFIC: CELL LINE DEVELOPMENT MARKET, BY SOURCE, 2018-2027 (USD MILLION)
  • TABLE 115 ASIA-PACIFIC: CELL LINE DEVELOPMENT MARKET, FOR NON-MAMMALIAN, BY TYPE, 2018-2027 (USD MILLION)
  • TABLE 116 ASIA-PACIFIC: CELL LINE DEVELOPMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
  • TABLE 117 ASIA-PACIFIC: CELL LINE DEVELOPMENT MARKET, BY APPLICATION, 2018-2027 (USD MILLION)
  • TABLE 118 ASIA-PACIFIC: CELL LINE DEVELOPMENT MARKET, FOR BIOPRODUCTION, BY TYPE, 2018-2027 (USD MILLION)
  • TABLE 119 ASIA-PACIFIC: CELL LINE DEVELOPMENT MARKET, FOR ANTIBODY PRODUCTION, BY TYPE, 2018-2027 (USD MILLION)
  • TABLE 120 CHINA: CELL LINE DEVELOPMENT MARKET, BY PRODUCT, 2018-2027 (USD MILLION)
  • TABLE 121 CHINA: CELL LINE DEVELOPMENT MARKET, BY SOURCE, 2018-2027 (USD MILLION)
  • TABLE 122 CHINA: CELL LINE DEVELOPMENT MARKET, FOR BY NON-MAMMALIAN, BY TYPE, 2018-2027 (USD MILLION)
  • TABLE 123 CHINA: CELL LINE DEVELOPMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
  • TABLE 124 CHINA: CELL LINE DEVELOPMENT MARKET, BY APPLICATION, 2018-2027 (USD MILLION)
  • TABLE 125 CHINA: CELL LINE DEVELOPMENT MARKET, FOR BIOPRODUCTION, BY TYPE, 2018-2027 (USD MILLION)
  • TABLE 126 CHINA: CELL LINE DEVELOPMENT MARKET, FOR ANTIBODY PRODUCTION, BY TYPE, 2018-2027 (USD MILLION)
  • TABLE 127 JAPAN: CELL LINE DEVELOPMENT MARKET, BY PRODUCT, 2018-2027 (USD MILLION)
  • TABLE 128 JAPAN: CELL LINE DEVELOPMENT MARKET, BY SOURCE, 2018-2027 (USD MILLION)
  • TABLE 129 JAPAN: CELL LINE DEVELOPMENT MARKET, FOR BY NON-MAMMALIAN, BY TYPE, 2018-2027 (USD MILLION)
  • TABLE 130 JAPAN: CELL LINE DEVELOPMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
  • TABLE 131 JAPAN: CELL LINE DEVELOPMENT MARKET, BY APPLICATION, 2018-2027 (USD MILLION)
  • TABLE 132 JAPAN: CELL LINE DEVELOPMENT MARKET, FOR BIOPRODUCTION, BY TYPE, 2018-2027 (USD MILLION)
  • TABLE 133 JAPAN: CELL LINE DEVELOPMENT MARKET, FOR ANTIBODY PRODUCTION, BY TYPE, 2018-2027 (USD MILLION)
  • TABLE 134 INDIA: CELL LINE DEVELOPMENT MARKET, BY PRODUCT, 2018-2027 (USD MILLION)
  • TABLE 135 INDIA: CELL LINE DEVELOPMENT MARKET, BY SOURCE, 2018-2027 (USD MILLION)
  • TABLE 136 INDIA: CELL LINE DEVELOPMENT MARKET, FOR BY NON-MAMMALIAN, BY TYPE, 2018-2027 (USD MILLION)
  • TABLE 137 INDIA: CELL LINE DEVELOPMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
  • TABLE 138 INDIA: CELL LINE DEVELOPMENT MARKET, BY APPLICATION, 2018-2027 (USD MILLION)
  • TABLE 139 INDIA: CELL LINE DEVELOPMENT MARKET, FOR BIOPRODUCTION, BY TYPE, 2018-2027 (USD MILLION)
  • TABLE 140 INDIA: CELL LINE DEVELOPMENT MARKET, FOR ANTIBODY PRODUCTION, BY TYPE, 2018-2027 (USD MILLION)
  • TABLE 141 SOUTH KOREA: CELL LINE DEVELOPMENT MARKET, BY PRODUCT, 2018-2027 (USD MILLION)
  • TABLE 142 SOUTH KOREA: CELL LINE DEVELOPMENT MARKET, BY SOURCE, 2018-2027 (USD MILLION)
  • TABLE 143 SOUTH KOREA: CELL LINE DEVELOPMENT MARKET, FOR BY NON-MAMMALIAN, BY TYPE, 2018-2027 (USD MILLION)
  • TABLE 144 SOUTH KOREA: CELL LINE DEVELOPMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
  • TABLE 145 SOUTH KOREA: CELL LINE DEVELOPMENT MARKET, BY APPLICATION, 2018-2027 (USD MILLION)
  • TABLE 146 SOUTH KOREA: CELL LINE DEVELOPMENT MARKET, FOR BIOPRODUCTION, BY TYPE, 2018-2027 (USD MILLION)
  • TABLE 147 SOUTH KOREA: CELL LINE DEVELOPMENT MARKET, FOR ANTIBODY PRODUCTION, BY TYPE, 2018-2027 (USD MILLION)
  • TABLE 148 AUSTRALIA: CELL LINE DEVELOPMENT MARKET, BY PRODUCT, 2018-2027 (USD MILLION)
  • TABLE 149 AUSTRALIA: CELL LINE DEVELOPMENT MARKET, BY SOURCE, 2018-2027 (USD MILLION)
  • TABLE 150 AUSTRALIA: CELL LINE DEVELOPMENT MARKET, FOR BY NON-MAMMALIAN, BY TYPE, 2018-2027 (USD MILLION)
  • TABLE 151 AUSTRALIA: CELL LINE DEVELOPMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
  • TABLE 152 AUSTRALIA: CELL LINE DEVELOPMENT MARKET, BY APPLICATION, 2018-2027 (USD MILLION)
  • TABLE 153 AUSTRALIA: CELL LINE DEVELOPMENT MARKET, FOR BIOPRODUCTION, BY TYPE, 2018-2027 (USD MILLION)
  • TABLE 154 AUSTRALIA: CELL LINE DEVELOPMENT MARKET, FOR ANTIBODY PRODUCTION, BY TYPE, 2018-2027 (USD MILLION)
  • TABLE 155 REST OF ASIA PACIFIC: CELL LINE DEVELOPMENT MARKET, BY PRODUCT, 2018-2027 (USD MILLION)
  • TABLE 156 REST OF ASIA PACIFIC: CELL LINE DEVELOPMENT MARKET, BY SOURCE, 2018-2027 (USD MILLION)
  • TABLE 157 REST OF ASIA PACIFIC: CELL LINE DEVELOPMENT MARKET, FOR BY NON-MAMMALIAN, BY TYPE, 2018-2027 (USD MILLION)
  • TABLE 158 REST OF ASIA PACIFIC: CELL LINE DEVELOPMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
  • TABLE 159 REST OF ASIA PACIFIC: CELL LINE DEVELOPMENT MARKET, BY APPLICATION, 2018-2027 (USD MILLION)
  • TABLE 160 REST OF ASIA PACIFIC: CELL LINE DEVELOPMENT MARKET, FOR BIOPRODUCTION, BY TYPE, 2018-2027 (USD MILLION)
  • TABLE 161 REST OF ASIA PACIFIC: CELL LINE DEVELOPMENT MARKET, FOR ANTIBODY PRODUCTION, BY TYPE, 2018-2027 (USD MILLION)
  • TABLE 162 REST OF THE WORLD: CELL LINE DEVELOPMENT MARKET, BY REGION, 2018-2027 (USD MILLION)
  • TABLE 163 REST OF THE WORLD: CELL LINE DEVELOPMENT MARKET, BY PRODUCT, 2018-2027 (USD MILLION)
  • TABLE 164 REST OF THE WORLD: CELL LINE DEVELOPMENT MARKET, BY SOURCE, 2018-2027 (USD MILLION)
  • TABLE 165 REST OF THE WORLD: CELL LINE DEVELOPMENT MARKET, FOR BY NON-MAMMALIAN, BY TYPE, 2018-2027 (USD MILLION)
  • TABLE 166 REST OF THE WORLD: CELL LINE DEVELOPMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
  • TABLE 167 REST OF THE WORLD: CELL LINE DEVELOPMENT MARKET, BY APPLICATION, 2018-2027 (USD MILLION)
  • TABLE 168 REST OF THE WORLD: CELL LINE DEVELOPMENT MARKET, FOR BIOPRODUCTION, BY TYPE, 2018-2027 (USD MILLION)
  • TABLE 169 REST OF THE WORLD: CELL LINE DEVELOPMENT MARKET, FOR ANTIBODY PRODUCTION, BY TYPE, 2018-2027 (USD MILLION)
  • TABLE 170 MIDDLE EAST: CELL LINE DEVELOPMENT MARKET, BY PRODUCT, 2018-2027 (USD MILLION)
  • TABLE 171 MIDDLE EAST: CELL LINE DEVELOPMENT MARKET, BY SOURCE, 2018-2027 (USD MILLION)
  • TABLE 172 MIDDLE EAST: CELL LINE DEVELOPMENT MARKET, FOR BY NON-MAMMALIAN, BY TYPE, 2018-2027 (USD MILLION)
  • TABLE 173 MIDDLE EAST: CELL LINE DEVELOPMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
  • TABLE 174 MIDDLE EAST: CELL LINE DEVELOPMENT MARKET, BY APPLICATION, 2018-2027 (USD MILLION)
  • TABLE 175 MIDDLE EAST: CELL LINE DEVELOPMENT MARKET, FOR BIOPRODUCTION, BY TYPE, 2018-2027 (USD MILLION)
  • TABLE 176 MIDDLE EAST: CELL LINE DEVELOPMENT MARKET, FOR ANTIBODY PRODUCTION, BY TYPE, 2018-2027 (USD MILLION)
  • TABLE 177 AFRICA: CELL LINE DEVELOPMENT MARKET, BY PRODUCT, 2018-2027 (USD MILLION)
  • TABLE 178 AFRICA: CELL LINE DEVELOPMENT MARKET, BY SOURCE, 2018-2027 (USD MILLION)
  • TABLE 179 AFRICA: CELL LINE DEVELOPMENT MARKET, FOR BY NON-MAMMALIAN, BY TYPE, 2018-2027 (USD MILLION)
  • TABLE 180 AFRICA: CELL LINE DEVELOPMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
  • TABLE 181 AFRICA: CELL LINE DEVELOPMENT MARKET, BY APPLICATION, 2018-2027 (USD MILLION)
  • TABLE 182 AFRICA: CELL LINE DEVELOPMENT MARKET, FOR BIOPRODUCTION, BY TYPE, 2018-2027 (USD MILLION)
  • TABLE 183 AFRICA: CELL LINE DEVELOPMENT MARKET, FOR ANTIBODY PRODUCTION, BY TYPE, 2018-2027 (USD MILLION)
  • TABLE 184 LATIN AMERICA: CELL LINE DEVELOPMENT MARKET, BY PRODUCT, 2018-2027 (USD MILLION)
  • TABLE 185 LATIN AMERICA: CELL LINE DEVELOPMENT MARKET, BY SOURCE, 2018-2027 (USD MILLION)
  • TABLE 186 LATIN AMERICA: CELL LINE DEVELOPMENT MARKET, FOR BY NON-MAMMALIAN, BY TYPE, 2018-2027 (USD MILLION)
  • TABLE 187 LATIN AMERICA: CELL LINE DEVELOPMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
  • TABLE 188 LATIN AMERICA: CELL LINE DEVELOPMENT MARKET, BY APPLICATION, 2018-2027 (USD MILLION)
  • TABLE 189 LATIN AMERICA: CELL LINE DEVELOPMENT MARKET, FOR BIOPRODUCTION, BY TYPE, 2018-2027 (USD MILLION)
  • TABLE 190 LATIN AMERICA: CELL LINE DEVELOPMENT MARKET, FOR ANTIBODY PRODUCTION, BY TYPE, 2018-2027 (USD MILLION)
  • TABLE 191 MAJOR PLAYERS IN THE GLOBAL CELL LINE DEVELOPMENT MARKET
  • TABLE 192 MOST ACTIVE PLAYER IN THE GLOBAL CELL LINE DEVELOPMENT MARKET
  • TABLE 193 PRODUCT LAUNCH/ PRODUCT APPROVAL
  • TABLE 194 MERGER/ACQUISITION
  • TABLE 195 PARTNERSHIP/ AGREEMENT
  • TABLE 196 EXPANSION/ INVESTMENT
  • TABLE 197 LONZA GROUP: PRODUCTS/SERVICES OFFERED
  • TABLE 198 LONZA GROUP: KEY DEVELOPMENTS
  • TABLE 199 SELEXIS SA: PRODUCTS/SERVICES OFFERED
  • TABLE 200 SELEXIS SA: KEY DEVELOPMENTS
  • TABLE 201 BOEHRINGER INGELHEIM INTERNATIONAL GMBH: PRODUCTS OFFERED
  • TABLE 202 BOEHRINGER INGELHEIM INTERNATIONAL GMBH: KEY DEVELOPMENTS
  • TABLE 203 THERMO FISHER SCIENTIFIC INC.: PRODUCTS OFFERED
  • TABLE 204 THERMO FISHER SCIENTIFIC INC.: KEY DEVELOPMENTS
  • TABLE 205 WUXI BIOLOGICS: PRODUCTS OFFERED
  • TABLE 206 WUXI BIOLOGICS: KEY DEVELOPMENTS
  • TABLE 207 RENTSCHLER BIOPHARMA SE: PRODUCTS/SERVICES OFFERED
  • TABLE 208 RENTSCHLER BIOPHARMA SE: KEY DEVELOPMENTS
  • TABLE 209 HORIZON DISCOVERY LTD: PRODUCTS OFFERED
  • TABLE 210 HORIZON DISCOVERY LTD: KEY DEVELOPMENTS
  • TABLE 211 SARTORIUS AG: PRODUCTS/SERVICES OFFERED
  • TABLE 212 SARTORIUS AG: KEY DEVELOPMENTS
  • TABLE 213 MERCK KGAA: PRODUCTS/SERVICES OFFERED
  • TABLE 214 FUJIFILM DIOSYNTH BIOTECHNOLOGIES INC.: PRODUCTS/SERVICES OFFERED
  • TABLE 215 FUJIFILM DIOSYNTH BIOTECHNOLOGIES INC.: KEY DEVELOPMENT

LIST OF FIGURES

  • FIGURE 1 GLOBAL CELL LINE DEVELOPMENT MARKET STRUCTURE
  • FIGURE 2 BOTTOM-UP AND TOP-DOWN APPROACHES
  • FIGURE 3 MARKET DYNAMICS: GLOBAL CELL LINE DEVELOPMENT MARKET
  • FIGURE 4 DRIVERS IMPACT ANALYSIS
  • FIGURE 5 RESTRAINTS IMPACT ANALYSIS
  • FIGURE 6 SUPPLY CHAIN ANALYSIS: GLOBAL CELL LINE DEVELOPMENT MARKET
  • FIGURE 7 CELL LINE DEVELOPMENT MARKET: PORTER'S FIVE FORCES MODEL
  • FIGURE 8 GLOBAL CELL LINE DEVELOPMENT MARKET, BY PRODUCT, 2020 & 2027 (USD MILLION)
  • FIGURE 9 GLOBAL: CELL LINE DEVELOPMENT MARKET, BY SOURCE, 2020 & 2027 (USD MILLION)
  • FIGURE 10 GLOBAL: CELL LINE DEVELOPMENT MARKET, BY TYPE, 2020 & 2027 (USD MILLION)
  • FIGURE 11 GLOBAL: CELL LINE DEVELOPMENT MARKET, BY APPLICATION, 2020 & 2027 (USD MILLION)
  • FIGURE 12 GLOBAL: CELL LINE DEVELOPMENT MARKET, BY REGION, 2020 & 2027 (USD MILLION)
  • FIGURE 13 NORTH AMERICA: CELL LINE DEVELOPMENT MARKET SHARE (%), BY COUNTRY, 2020
  • FIGURE 14 EUROPE: CELL LINE DEVELOPMENT MARKET SHARE (%), BY COUNTRY, 2020
  • FIGURE 15 ASIA-PACIFIC: CELL LINE DEVELOPMENT MARKET SHARE (%), BY COUNTRY, 2020
  • FIGURE 16 REST OF THE WORLD: CELL LINE DEVELOPMENT MARKET SHARE (%), BY REGION, 2020
  • FIGURE 17 GLOBAL CELL LINE DEVELOPMENT MAJOR PLAYERS MARKET SHARE (%) ANALYSIS, 2020
  • FIGURE 18 BENCHMARKING OF MAJOR COMPETITORS
  • FIGURE 19 MAJOR STRATEGY ADOPTED BY KEY PLAYERS IN THE GLOBAL CELL LINE DEVELOPMENT MARKET
  • FIGURE 20 COMPETITIVE BENCHMARKING: GLOBAL CELL LINE DEVELOPMENT MRKET
  • FIGURE 21 GLOBAL CELL LINE DEVELOPMENT MARKET: COMPETITIVE LANDSCAPE
  • FIGURE 22 SALES (USD MILLION), 2020
  • FIGURE 23 R&D EXPENDITURE (USD MILLION), 2020
  • FIGURE 24 LONZA GROUP: FINANCIAL OVERVIEW SNAPSHOT
  • FIGURE 25 LONZA GROUP: SWOT ANALYSIS
  • FIGURE 26 SELEXIS SA: FINANCIAL OVERVIEW SNAPSHOT
  • FIGURE 27 SELEXIS SA: SWOT ANALYSIS
  • FIGURE 28 BOEHRINGER INGELHEIM INTERNATIONAL GMBH: FINANCIAL OVERVIEW SNAPSHOT
  • FIGURE 29 BOEHRINGER INGELHEIM INTERNATIONAL GMBH: SWOT ANALYSIS
  • FIGURE 30 THERMO FISHER SCIENTIFIC INC.: FINANCIAL OVERVIEW SNAPSHOT
  • FIGURE 31 THERMO FISHER SCIENTIFIC INC.: SWOT ANALYSIS
  • FIGURE 32 WUXI BIOLOGICS: FINANCIAL OVERVIEW SNAPSHOT
  • FIGURE 33 WUXI BIOLOGICS: SWOT ANALYSIS
  • FIGURE 34 SARTORIUS AG: FINANCIAL OVERVIEW SNAPSHOT
  • FIGURE 35 SARTORIUS AG: SWOT ANALYSIS
  • FIGURE 36 MERCK KGAA: FINANCIAL OVERVIEW SNAPSHOT
  • FIGURE 37 MERCK KGAA: SWOT ANALYSIS
  • FIGURE 38 FUJIFILM DIOSYNTH BIOTECHNOLOGIES: FINANCIAL OVERVIEW SNAPSHOT
目次
Product Code: MRFR/HC/7659-CR

Market Synopsys

The global cell line development market is evaluated to exhibit a significant CAGR of 11.3% during the review period to reach USD 10,829.9 million by the end of 2027. Cell Line Development is used for drug target recognition and production of biologic drugs. These cell line development methods are used in Cell surface expression screening, Cell viability, Clone productivity screening and titer, Comparison of traditional cloning methods with f.sight, COVID-19 and Infectious Disease Research, Monoclonality, Single cell sorting etc. the global market growth is driven by the growing demand for monoclonal antibodies, expanding biotechnology industry, increasing vaccine production worldwide. However, the complicated method for developing stable and authentic cell lines, need of skilled workers and the high maintenance cost is expected to restrain the global market during the review period.

The global cell line development market is expected to witness a significant market expansion during the review period. The rising application of cell lines in biotech & pharmaceutical companies and hospitals and the increasing incidences of chronic diseases are set to accelerate the global market during the review period.

In this manner, the rising reception of mammalian hotspots for the development of monoclonal antibodies and the rising interest for communicating complex proteins like people are expected to give huge learning experiences.

Market Segmentation

Global Cell Line Development market is classified based on type, product source, application, and region.

The type of segment classifies the market into Primary Cell Lines, Hybridomas, Recombinant Cell Line, and Continuous Cell Lines. Based on Product the market has been divided into Equipment and Media and Reagents.

The Source type is bifurcated into Mammalian Cells and Non-Mammalian Cells, the Non-Mammalian type is further divided into Insects and Amphibians.

The Application segment is categorized into Bio-production, drug discovery, Tissue Engineering, and others. Bio-production category is further divided into antibody production, enzyme production, hormone production, and others. The antibody production type is again bifurcated as mono and multi types.

Regional Analysis

The examination research centers across North America are progressively modernizing their methodology and utilizing cell line development instruments for immunizer creation, drug digestion and cytotoxicity, tissue designing, immunization creation, concentrating on quality articulation, creation of helpful proteins, and different purposes. In addition, the market in the locale is driven by the rising R&D in the drug and biopharmaceutical industry, zeroing in on cell line development. In October 2019, ATCC sent off another validation administration that assists scientists with affirming the character of mouse cell lines without any problem. The help was created in alongside the National Institutes for Standards and Technology.

Asia-Pacific is expected to be the quickest developing provincial market over the appraisal time frame because of quickly further developing medical services framework, expanding interest for monoclonal antibodies to treat different illnesses, for example, myocardial illness and malignant growth, utilization of cell line for immunization development by the organizations, and government support in controlling biotechnology items around here.

Major Players

The key companies associated with a global cell line development market research are Pfizer (US), Novartis (Switzerland), Cellectis (France), and bioMerieux SA (France)

COVID 19 Impacts

We are continuously tracking the impact of the COVID-19 pandemic on various industries and verticals within all domains. Our research reports include the same and help you understand the drop and rise, owing to the impact of COVID-19 on the industries. Also, we help you to identify the gap between the demand and supply of your interested market. Moreover, the report helps you with the analysis, amended government regulations, and many other useful insights.

TABLE OF CONTENTS

TABLE OF CONTENTS

1 EXECUTIVE SUMMARY

  • 1.1 MARKET SYNOPSIS

2 MARKET INTRODUCTION

  • 2.1 SCOPE OF THE STUDY
  • 2.2 RESEARCH OBJECTIVE
  • 2.3 LIST OF ASSUMPTIONS & LIMITATIONS

3 RESEARCH METHODOLOGY

  • 3.1 DATA MINING
  • 3.2 SECONDARY RESEARCH
  • 3.3 PRIMARY RESEARCH
    • 3.3.1 PRIMARY INTERVIEWS AND INFORMATION GATHERING PROCESS
    • 3.3.2 BREAKDOWN OF PRIMARY RESPONDENTS
  • 3.4 FORECASTING TECHNIQUES
  • 3.5 RESEARCH METHODOLOGY FOR MARKET SIZE ESTIMATION
    • 3.5.1 BOTTOM-UP APPROACH
    • 3.5.2 TOP-DOWN APPROACH
  • 3.6 DATA TRIANGULATION
  • 3.7 VALIDATION

4 MARKET DYNAMICS

  • 4.1 OVERVIEW
  • 4.2 DRIVERS
    • 4.2.1 RISING R&D IN THE PHARMACEUTICAL AND BIOTECHNOLOGY INDUSTRIES
    • 4.2.2 INCREASING APPLICATION OF CELL LINES IN BIOTECH & PHARMACEUTICAL COMPANIES AND HOSPITALS
    • 4.2.3 RISING PREVALENCE OF CANCER AND OTHER CHRONIC DISEASES
  • 4.3 RESTRAINTS
    • 4.3.1 HIGH MAINTENANCE COSTS AND DEARTH OF SKILLED STAFF
    • 4.3.2 COMPLEXITY INVOLVED IN DEVELOPING STABLE AND AUTHENTIC CELL LINES
  • 4.4 OPPORTUNITY
    • 4.4.1 RISING ADOPTION OF MAMMALIAN SOURCES FOR ANTIBODY PRODUCTION
    • 4.4.2 TECHNOLOGICAL INNOVATION IN CELL LINE DEVELOPMENT

5 MARKET FACTOR ANALYSIS

  • 5.1 SUPPLY CHAIN ANALYSIS
    • 5.1.1 R&D
    • 5.1.2 MANUFACTURING
    • 5.1.3 SALES & MARKETING
    • 5.1.4 POST-SALES MONITORING
  • 5.2 PORTER'S FIVE FORCES MODEL
    • 5.2.1 THREAT OF NEW ENTRANTS
    • 5.2.2 BARGAINING POWER OF SUPPLIERS
    • 5.2.3 THREAT OF SUBSTITUTES
    • 5.2.4 BARGAINING POWER OF BUYERS
    • 5.2.5 INTENSITY OF RIVALRY
  • 5.3 IMPACT OF COVID-19 ON THE GLOBAL CELL LINE DEVELOPMENT MARKET
    • 5.3.1 OVERVIEW
    • 5.3.2 IMPACT ON DEMAND
    • 5.3.3 IMPACT ON SUPPLY
    • 5.3.4 IMPACT ON TRADE (IMPORT/EXPORT)
    • 5.3.5 IMPACT ON KEY PLAYERS

6 GLOBAL CELL LINE DEVELOPMENT MARKET, BY PRODUCT

  • 6.1 OVERVIEW
  • 6.2 EQUIPMENT
  • 6.3 REAGENTS & MEDIA

7 GLOBAL CELL LINE DEVELOPMENT MARKET, BY SOURCE

  • 7.1 OVERVIEW
  • 7.2 MAMMALIAN
  • 7.3 NON-MAMMALIAN
    • 7.3.1 AMPHIBIANS
    • 7.3.2 INSECTS

8 GLOBAL CELL LINE DEVELOPMENT MARKET, BY TYPE

  • 8.1 OVERVIEW
  • 8.2 RECOMBINANT CELL LINES
  • 8.3 HYBRIDOMAS
  • 8.4 CONTINUOUS CELL LINES
  • 8.5 PRIMARY CELL LINES

9 GLOBAL CELL LINE DEVELOPMENT MARKET, BY APPLICATION

  • 9.1 OVERVIEW
  • 9.2 BIOPRODUCTION
    • 9.2.1 MARKET TRENDS AND COMPARATIVE GROWTH RATE OF BISPECIFICS/MULTISPECIFICS AND CELL LINE DEVELOPMENT MARKET
    • 9.2.2 ANTIBODY PRODUCTION
      • 9.2.2.1 MONO
      • 9.2.2.2 BI/MULTI
    • 9.2.3 ENZYME PRODUCTION
    • 9.2.4 HORMONE PRODUCTION
    • 9.2.5 OTHERS
  • 9.3 DRUG DISCOVERY
  • 9.4 TISSUE ENGINEERING
  • 9.5 OTHERS

10 GLOBAL CELL LINE DEVELOPMENT MARKET, BY REGION

  • 10.1 OVERVIEW
  • 10.2 NORTH AMERICA
    • 10.2.1 US
    • 10.2.2 CANADA
  • 10.3 EUROPE
    • 10.3.1 GERMANY
    • 10.3.2 UK
    • 10.3.3 FRANCE
    • 10.3.4 ITALY
    • 10.3.5 SPAIN
    • 10.3.6 SWITZERLAND
    • 10.3.7 REST OF EUROPE
  • 10.4 ASIA-PACIFIC
    • 10.4.1 CHINA
    • 10.4.2 JAPAN
    • 10.4.3 INDIA
    • 10.4.4 SOUTH KOREA
    • 10.4.5 AUSTRALIA
    • 10.4.6 REST OF ASIA PACIFIC
  • 10.5 REST OF THE WORLD
    • 10.5.1 MIDDLE EAST
    • 10.5.2 AFRICA
    • 10.5.3 LATIN AMERICA

11 COMPETITIVE LANDSCAPE

  • 11.1 OVERVIEW
  • 11.2 GLOBAL CELL LINE DEVELOPMENT MARKET: COMPANY SHARE ANALYSIS
  • 11.3 COMPETITIVE BENCHMARKING
  • 11.4 MAJOR GROWTH STRATEGY IN THE GLOBAL CELL LINE DEVELOPMENT MARKET
  • 11.5 THE LEADING PLAYER IN TERMS OF THE NUMBER OF DEVELOPMENTS IN THE GLOBAL CELL LINE DEVELOPMENT MARKET
  • 11.6 KEY DEVELOPMENT ANALYSIS
  • 11.7 KEY DEVELOPMENTS & GROWTH STRATEGIES
    • 11.7.1 PRODUCT LAUNCH/ PRODUCT APPROVAL
    • 11.7.2 MERGER/ACQUISITION
    • 11.7.3 PARTNERSHIP/ AGREEMENT
    • 11.7.4 EXPANSION/ INVESTMENT
  • 11.8 FINANCIAL MATRIX
    • 11.8.1 SALES (USD MILLION), 2020
    • 11.8.2 R&D EXPENDITURE (USD MILLION), 2020

12 COMPANY PROFILES

  • 12.1 LONZA GROUP
    • 12.1.1 COMPANY OVERVIEWS
    • 12.1.2 FINANCIAL OVERVIEW
    • 12.1.3 PRODUCTS/SERVICES OFFERED
    • 12.1.4 KEY DEVELOPMENTS
    • 12.1.5 SWOT ANALYSIS
    • 12.1.6 KEY STRATEGIES
  • 12.2 SELEXIS SA
    • 12.2.1 COMPANY OVERVIEW
    • 12.2.2 FINANCIAL OVERVIEW
    • 12.2.3 PRODUCTS/SERVICES OFFERED
    • 12.2.4 KEY DEVELOPMENTS
    • 12.2.5 SWOT ANALYSIS
    • 12.2.6 KEY STRATEGIES
  • 12.3 BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    • 12.3.1 COMPANY OVERVIEW
    • 12.3.2 FINANCIAL OVERVIEW
    • 12.3.3 PRODUCTS OFFERED
    • 12.3.4 KEY DEVELOPMENTS
    • 12.3.5 SWOT ANALYSIS
    • 12.3.6 KEY STRATEGIES
  • 12.4 THERMO FISHER SCIENTIFIC INC.
    • 12.4.1 COMPANY OVERVIEW
    • 12.4.2 FINANCIAL OVERVIEW
    • 12.4.3 PRODUCTS OFFERED
    • 12.4.4 KEY DEVELOPMENTS.
    • 12.4.5 SWOT ANALYSIS
    • 12.4.6 KEY STRATEGIES
  • 12.5 WUXI BIOLOGICS
    • 12.5.1 COMPANY OVERVIEW
    • 12.5.2 FINANCIAL OVERVIEW
    • 12.5.3 PRODUCTS OFFERED
    • 12.5.4 KEY DEVELOPMENTS
    • 12.5.5 SWOT ANALYSIS
    • 12.5.6 KEY STRATEGIES
  • 12.6 RENTSCHLER BIOPHARMA SE
    • 12.6.1 COMPANY OVERVIEW
    • 12.6.2 FINANCIAL OVERVIEW
    • 12.6.3 PRODUCTS/SERVICES OFFERED
    • 12.6.4 KEY DEVELOPMENTS
    • 12.6.5 KEY STRATEGIES
  • 12.7 HORIZON DISCOVERY LTD
    • 12.7.1 COMPANY OVERVIEW
    • 12.7.2 FINANCIAL OVERVIEW
    • 12.7.3 PRODUCTS OFFERED
    • 12.7.4 KEY DEVELOPMENTS
    • 12.7.5 KEY STRATEGIES
  • 12.8 SARTORIUS AG
    • 12.8.1 COMPANY OVERVIEW
    • 12.8.2 FINANCIAL OVERVIEW
    • 12.8.3 PRODUCTS/SERVICES OFFERED
    • 12.8.4 KEY DEVELOPMENTS
    • 12.8.5 SWOT ANALYSIS
    • 12.8.6 KEY STRATEGIES
  • 12.9 MERCK KGAA
    • 12.9.1 COMPANY OVERVIEW
    • 12.9.2 FINANCIAL OVERVIEW
    • 12.9.3 PRODUCTS OFFERED
    • 12.9.4 KEY DEVELOPMENTS
    • 12.9.5 SWOT ANALYSIS
    • 12.9.6 KEY STRATEGIES
  • 12.10 FUJIFILM DIOSYNTH BIOTECHNOLOGIES INC.
    • 12.10.1 COMPANY OVERVIEW
    • 12.10.2 FINANCIAL OVERVIEW
    • 12.10.3 PRODUCTS/SERVICES OFFERED
    • 12.10.4 KEY DEVELOPMENT
    • 12.10.5 KEY STRATEGIES

13 APPENDIX

  • 13.1 REFERENCES
  • 13.2 RELATED REPORTS